🇺🇸 Tanreqing capsule in United States
1 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 1
Most-reported reactions
- Granulocytopenia — 1 report (100%)
Other Respiratory approved in United States
Frequently asked questions
Is Tanreqing capsule approved in United States?
Tanreqing capsule does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Tanreqing capsule in United States?
Jiangsu Famous Medical Technology Co., Ltd. is the originator. The local marketing authorisation holder may differ — check the official source linked above.